Quest Diagnostics Inc. (DGX): Price and Financial Metrics
DGX Price/Volume Stats
Current price | $133.11 | 52-week high | $148.62 |
Prev. close | $131.06 | 52-week low | $119.59 |
Day low | $131.18 | Volume | 888,000 |
Day high | $133.41 | Avg. volume | 1,053,229 |
50-day MA | $127.84 | Dividend yield | 2.2% |
200-day MA | $132.02 | Market Cap | 14.78B |
DGX Stock Price Chart Interactive Chart >
DGX POWR Grades
- DGX scores best on the Quality dimension, with a Quality rank ahead of 82.77% of US stocks.
- DGX's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- DGX ranks lowest in Momentum; there it ranks in the 26th percentile.
DGX Stock Summary
- QUEST DIAGNOSTICS INC's market capitalization of $15,704,920,381 is ahead of 87.16% of US-listed equities.
- As for revenue growth, note that DGX's revenue has grown -9.69% over the past 12 months; that beats the revenue growth of merely 22.59% of US companies in our set.
- In terms of volatility of its share price, DGX is more volatile than merely 4.12% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to QUEST DIAGNOSTICS INC are PKG, BEN, BRO, COTY, and HRL.
- DGX's SEC filings can be seen here. And to visit QUEST DIAGNOSTICS INC's official web site, go to www.questdiagnostics.com.
DGX Valuation Summary
- In comparison to the median Healthcare stock, DGX's price/sales ratio is 22.73% lower, now standing at 1.7.
- Over the past 243 months, DGX's price/earnings ratio has gone up 1.6.
Below are key valuation metrics over time for DGX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
DGX | 2023-12-29 | 1.7 | 2.4 | 20.3 | 18.2 |
DGX | 2023-12-28 | 1.7 | 2.4 | 20.3 | 18.2 |
DGX | 2023-12-27 | 1.7 | 2.4 | 20.3 | 18.2 |
DGX | 2023-12-26 | 1.7 | 2.4 | 20.2 | 18.1 |
DGX | 2023-12-22 | 1.7 | 2.4 | 20.1 | 18.1 |
DGX | 2023-12-21 | 1.6 | 2.4 | 20.0 | 18.1 |
DGX Growth Metrics
- Its 2 year revenue growth rate is now at 39.47%.
- Its year over year net cashflow from operations growth rate is now at -20.37%.
- Its 3 year revenue growth rate is now at 41.67%.
The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 9,883 | 1,718 | 946 |
2022-09-30 | 10,294 | 1,865 | 1,235 |
2022-06-30 | 10,582 | 1,924 | 1,484 |
2022-03-31 | 10,679 | 1,982 | 1,881 |
2021-12-31 | 10,788 | 2,233 | 1,995 |
2021-09-30 | 11,046 | 2,293 | 2,184 |
DGX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DGX has a Quality Grade of B, ranking ahead of 93.32% of graded US stocks.
- DGX's asset turnover comes in at 0.812 -- ranking 31st of 81 Healthcare stocks.
- SSY, LH, and BIOC are the stocks whose asset turnover ratios are most correlated with DGX.
The table below shows DGX's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.812 | 0.403 | 0.404 |
2021-06-30 | 0.805 | 0.412 | 0.417 |
2021-03-31 | 0.750 | 0.404 | 0.340 |
2020-12-31 | 0.709 | 0.385 | 0.277 |
2020-09-30 | 0.643 | 0.362 | 0.221 |
2020-06-30 | 0.604 | 0.334 | 0.162 |
DGX Price Target
For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $157.67 | Average Broker Recommendation | 1.56 (Moderate Buy) |
Quest Diagnostics Inc. (DGX) Company Bio
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)
Latest DGX News From Around the Web
Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.
Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare ConferenceQuest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024, at 6:45 p.m. Eastern Time. |
Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical OfficerQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that Yuri A. Fesko, M.D., has been named senior vice president and chief medical officer (CMO), effective immediately. |
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test PanelQuest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic. |
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid ArthritisRelationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE / December 19, 2023 / Quest Diagnostics (NYSE:DGX), the world's leading provider of ... |
Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test PanelQuest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illi |
DGX Price Returns
1-mo | 5.93% |
3-mo | -2.95% |
6-mo | 10.45% |
1-year | -2.39% |
3-year | 9.88% |
5-year | 63.88% |
YTD | -2.95% |
2023 | -10.05% |
2022 | -7.80% |
2021 | 47.86% |
2020 | 14.11% |
2019 | 31.13% |
DGX Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching DGX
Want to do more research on Quest Diagnostics Inc's stock and its price? Try the links below:Quest Diagnostics Inc (DGX) Stock Price | Nasdaq
Quest Diagnostics Inc (DGX) Stock Quote, History and News - Yahoo Finance
Quest Diagnostics Inc (DGX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...